Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
Konda B, Sherman EJ, Massarelli E, Nieva J, Muzaffar J, Morris Iii JC, Ryder M, Ho AL, Agulnik M, Wei L, Handley D, Moses C, Jacob R, Wright J, Streicher H, Carson W, Shah MH. Konda B, et al. Among authors: massarelli e. J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210/clinem/dgae512. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39133806
Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors.
Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan YC, Cho H, Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, Massarelli E, Kulkarni P, Zeng Y, Salgia R. Guo L, et al. Among authors: massarelli e. iScience. 2023 Jul 10;26(8):107302. doi: 10.1016/j.isci.2023.107302. eCollection 2023 Aug 18. iScience. 2023. PMID: 37554452 Free PMC article.
A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer.
Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Nasser MW, Batra SK, Orban J, Jolly MK, Massarelli E, Kulkarni P, Salgia R. Mohanty A, et al. Among authors: massarelli e. iScience. 2020 Aug 22;23(9):101496. doi: 10.1016/j.isci.2020.101496. eCollection 2020 Sep 25. iScience. 2020. PMID: 32947124 Free PMC article.
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S, Liu C, Liu D, Liu W, Liu Y, Ma H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Zhong R, Li F, Rosell R, Provencio M, Massarelli E, Antonoff MB, Hida T, de Perrot M, Lin SH, Di Maio M, Rossi A, De Ruysscher D, Ramirez RA, Dempke WCM, Camidge DR, Guibert N, Califano R, Wang Q, Ren S, Zhou C, He J. Liang W, et al. Among authors: massarelli e. Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63. Transl Lung Cancer Res. 2020. PMID: 33489828 Free PMC article. Review. No abstract available.
Erratum: A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer.
Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Wu X, Mambetsariev I, Nelson M, Subbalakshmi AR, Guo L, Arvanitis LD, Nasser MW, Batra SK, Orban J, Jolly MK, Massarelli E, Kulkarni P, Salgia R. Mohanty A, et al. Among authors: massarelli e. iScience. 2020 Oct 23;23(11):101679. doi: 10.1016/j.isci.2020.101679. eCollection 2020 Nov 20. iScience. 2020. PMID: 33134900 Free PMC article.
Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E. Florez N, et al. Among authors: massarelli e. Oncologist. 2024 Sep 5:oyae228. doi: 10.1093/oncolo/oyae228. Online ahead of print. Oncologist. 2024. PMID: 39237103 Free article.
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, Felip E. Neal JW, et al. Among authors: massarelli e. JTO Clin Res Rep. 2024 Mar 20;5(10):100666. doi: 10.1016/j.jtocrr.2024.100666. eCollection 2024 Oct. JTO Clin Res Rep. 2024. PMID: 39318387 Free PMC article.
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M. Segal NH, et al. Among authors: massarelli e. Eur J Cancer. 2019 Mar;109:154-161. doi: 10.1016/j.ejca.2018.12.029. Epub 2019 Feb 4. Eur J Cancer. 2019. PMID: 30731276 Clinical Trial.
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee PP, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. Zhao D, et al. Among authors: massarelli e. Lung Cancer. 2020 Aug;146:174-181. doi: 10.1016/j.lungcan.2020.05.025. Epub 2020 May 24. Lung Cancer. 2020. PMID: 32554069 Free PMC article.
123 results